Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer

Sui, Weiguo; Ou, Minglin; Chen, Jiejing; Wan, Youhua; Peng, Hongbo; Qi, Min‐Fang; Huang, He; Dai, Yong

doi:10.1186/1477-7819-7-83

Cited by 32 publications

(23 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A few of studies [11,[17][18][19] show a concordance rate between IHC 3+ and discordance rate between IHC 2+ with FISH. But, other studies [14,20] show a concordance rate between IHC 2+ and FISH. Therefore, agreement between IHC and FISH are still controversial, in our concordance in the cases of IHC 3+ is similar with theirs, but there are some differences in the cases of IHC 2+.…”

Section: Discussionmentioning

confidence: 79%

“…Therefore, agreement between IHC and FISH are still controversial, in our concordance in the cases of IHC 3+ is similar with theirs, but there are some differences in the cases of IHC 2+. This may due to the different sensitivity and specificity of the antibodies and probe used in this study, [14] or because of subjective interpretative variation in reporting, variable pre-analytical conditions, imperfect IHC methodology [19].…”

Section: Discussionmentioning

confidence: 99%

“…Concordance rates were 32.4% for IHC 2+ and 81.25% for IHC 3+. [14] In other hand, discordance rates were 67.6% for IHC 2+ and 18.75% for IHC 3+ (Kappa=0.108, P<0.001) ( Table 1).…”

Section: Ihc and Fishmentioning

confidence: 94%

See 2 more Smart Citations

Comparison of IHC, FISH, ER and PR in Breast Cancer in Western Iran

Payandeh¹,

Sadeghi²,

Sadeghi³

et al. 2014

AJCP

View full text Add to dashboard Cite

To evaluate the concordance and discordance between IHC and FISH results for detection of Her2/neu protein, analyses of ER and PR, and also evaluation of the benefit of adjuvant trastuzumab in patients diagnosed with human epidermal growth factor receptor 2 (HER2) -positive invasive ductal carcinoma enrolled onto the Herceptin adjuvant. IHC analysis of ER, PR and HER2 was performed in 133 patients of breast cancer with invasive ductal carcinoma. 90(67.6%) cases were confirmed by FISH. Statistical analysis was performed with IBM SPSS version 19, Kaplan-Meier method and log-rank test. Age mean of patients was 46.39±10.81 years (range, 24-78 years). Concordance rates between IHC and FISH were 32.4% for IHC 2+ and 81.25% for IHC 3+ (P<0.001). There were 17 and 56 patients of IHC 2+ and 3+ with ER positive and also 23 and 59 patients of IHC 2+ and 3+ had PR positive.The 83 patients had age ≤50 years and 50 patients had >50 years. Of 133 the patients, 48(36.1%) patients were treated with trastuzumab and 85(63.9%) were treated without trastuzumab. The overall survival(OS) for patients treating with trastuzumab were mean of 37.8 months and the OS for patients treating without trastuzumab were mean of 20.8 months (P<0.05). The results are that trastuzumab therapy is effective and improves the survival of HER2-positive breast cancer patients and trastuzumab therapy is effective and tolerated for breast cancer with Her-2 positive. There is a statistically significant relationship between ER positive with PR positive and ER negative with PR negative that these results need to more studies with more patients in the world.

show abstract

Section: Discussionmentioning

confidence: 79%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of IHC, FISH, ER and PR in Breast Cancer in Western Iran

Payandeh¹,

Sadeghi²,

Sadeghi³

et al. 2014

AJCP

View full text Add to dashboard Cite

show abstract

“…Gene amplification could be demonstrated only in some of the samples that are found 2+ by IHC (Yeh). Studies have reported that FISH positivity in IHC 2+ samples varies between 7% and 89% (Ciampa et al, 2006;Rossi et al, 2006;Kuo et al, 2007;Sui et al, 2009;Goud et al, 2012;Zhang et al, 2012). Such diverse results might be due to the differences in the number of patients included in studies, centers' and/or pathologists' experience, and the test kits used.…”

Section: Discussionmentioning

confidence: 99%

HER2/neu Status in Breast Cancer Specimens: Comparison of Immunohistochemistry (IHC) and Fluorescence in situ Hybridization (FISH) Methods

Sağlıcan¹,

İnce²

2015

Int. J. Morphol.

View full text Add to dashboard Cite

SUMMARY: HER2 amplification or overexpression is considered as disease outcome and a predictive marker of response to treatment in breast cancer. The present study aimed to compare the results of IHC and FISH for determining HER2 and to search the interpretational differences. Samples (n= 169), of which 31 were the paraffin blocks sent from outer centers, that underwent FISH analysis for HER-2 were included. Samples were re-reviewed by IHC in our laboratory. FISH test was negative in 131 (77.5%) and positive in 38 (22.5%). When those with previous IHC 0-1+ were re-reviewed, the results were found again 0-1+ and none of them was FISH positive. Inconsistency between re-reviewed IHC and previous IHC results was 25% for those with 2+ score and 11% for those with 3+ score. Consistency between IHC and FISH was 17% and 67% for previous IHC 2+ and 3+, respectively, whereas it was 23% and %75 for re-reviewed IHC 2+ and 3+, respectively. Whilst 79% of the samples evaluated as 2+ by the inexperienced pathologist were found to be 0-1+ on the re-review, all of them were FISH negative. According to our results, we suggest that samples with IHC 2+ should be re-reviewed by consulting with an experienced pathologist.

show abstract

“…However, the sensitivity and specificity of the assay vary significantly depending on commercial antibody used. By contrast, FISH method is more standardized and less variable and has, therefore, emerged as a ''gold standard'' for assessment of HER2 status [18][19][20][21][22][23][24].…”

Section: Introductionmentioning

confidence: 99%

Intratumoral Heterogeneity Determines Discordant Results of Diagnostic Tests for Human Epidermal Growth Factor Receptor (HER) 2 in Gastric Cancer Specimens

Yang

Luo

et al. 2011

Cell Biochem Biophys

View full text Add to dashboard Cite

Accurate assessment of human epidermal growth factor receptor (HER) 2 is essential for efficient selection of patients who may benefit from therapies targeting this surface receptor (e.g., trastuzumab). Intratumoral heterogeneity of HER2 expression may potentially contribute to inaccurate assessment of HER2 status. To clarify intratumoral heterogeneity of HER2 expression and its potential clinical impact on assessment of HER2 status, we analyzed 148 endoscopic biopsy specimens and 117 excisional tumor specimens collected from 148 patients with primary gastric cancer. Specifically, we assessed HER2 protein overexpression and gene amplification using, respectively, immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). There were 28 IHC-positive cases and 25 FISH-positive cases among these 148 patients. Heterogeneous HER2 protein expression was demonstrated in 23 of 29 (79.3%) IHC-positive cases, while gene expression heterogeneity was found in 11 of 25 (44.0%) FISH-positive cases. Intratumoral heterogeneity was the main reason of discordant results between IHC and FISH or between endoscopic biopsy and excisional tumor specimens. The clinical significance and impact of intratumoral HER2 expression heterogeneity on treatment outcome in gastric cancer require further studies.

show abstract

Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer

Abstract: Background: The concordance rate between IHC and FISH according to clinical performance is still controversial. We report a prospective study to reflect the concordance between IHC and FISH in Guilin city, People's Republic of China.

Cited by 32 publications

References 21 publications

Comparison of IHC, FISH, ER and PR in Breast Cancer in Western Iran

Comparison of IHC, FISH, ER and PR in Breast Cancer in Western Iran

HER2/neu Status in Breast Cancer Specimens: Comparison of Immunohistochemistry (IHC) and Fluorescence in situ Hybridization (FISH) Methods

Intratumoral Heterogeneity Determines Discordant Results of Diagnostic Tests for Human Epidermal Growth Factor Receptor (HER) 2 in Gastric Cancer Specimens

Contact Info

Product

Resources

About